See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Avestria Ventures invests in women's health and female-led life science ventures, defining women's health as conditions affecting women exclusively (such as menopause), differently (such as cardiovascular disease), or disproportionately (such as Alzheimer's). The firm believes these markets are overlooked and undervalued — with only 1% of all venture capital for healthcare directed toward women's health companies, and only 1.9% of all VC going to female founders in 2022. Avestria seeks out early-stage businesses with products or services that utilize technology and/or data to improve healthcare quality, improve access, lower costs, or empower patients. To achieve commercial success, portfolio companies must be evidence-based, induce clinical or behavioral change, possess scalable commercialization plans accounting for healthcare policy and reimbursement, and maintain a sustainable competitive advantage.
Notable quotes
“Men still represent approximately 85% of the investment partners at venture capital firms, and many of them are missing out on great investment opportunities when they underinvest in women's health and female entrepreneurs.”
“We believe that both of our focus areas – women's health and female-led life science companies – are ripe for innovation. And the two exits we've already had indicate that strategic investors are beginning to draw the same conclusion.”
“Investing in women's health betters not just individual women but also families, workforces, and economies. Plus, investing in female founders — who are the usual founders of women's health companies — offers economic advantages as well as social ones.”
Team
Tracy Dooley
Partner
Margot Shapiro
Advisor, Venture Partner
Stephanie Jin
Investor
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Mercy BioAnalytics | Series B | $59m | 2025-09-03 |
| Midi Health | Series B | $60m | 2024-04-24 |
| Axena Health | Series A Extension | $9m | 2024-06-01 |
| May Health | Series B | $25m | 2024-05-01 |
| Alydia Health | Acquired (Organon) | — | 2021-06-16 |
| Antiva Biosciences | Series D | $31m | 2021-11-02 |
| AOA Dx | Seed | $7m | 2022-09-13 |
| Raydiant Oximetry | Series A | $5m | 2021-11-03 |
| Avation Medical | Series C | $22m | 2024-01-01 |
| Uqora | Acquired (Pharmavite) | — | 2021-07-01 |
Frequent co-investors
Fit check
Is Avestria Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit